MetaADEDB 2.0 @ LMMD
5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
(MCIACXAZCBVDEE-CUUWFGFTSA-N)
Structure
SMILES
CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@]12OC[C@@](O1)(CO)[C@H]([C@@H]([C@H]2O)O)O
Type(s)
Approved; Investigational
ATC code(s)
A10BD23; A10BD24; A10BK04
Molecular Formula:
C22H25ClO7
Molecular Weight:
436.883
Log P:
1.3565
Hydrogen Bond Acceptor:
7
Hydrogen Bond Donor:
4
TPSA:
108.61
CAS Number(s):
1210344-57-2
Synonym(s)
1.
5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
2.
PF 04971729
3.
PF-04971729
4.
PF04971729
5.
ertugliflozin
External Link(s)
MeSHC570288
PubChem Compound44814423
BindingDB50342885
CHEMBLCHEMBL1770248
DrugBankDB11827
DrugCentral5270
IUPHAR/BPS Guide to PHARMACOLOGY8376
KEGGdr:D10313
Therapeutic Target DatabaseD0Q3VE
D0H4JC
ZINC68197809
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Urinary tract infectionFAERS: 20US FAERS
2NauseaFAERS: 14US FAERS
3No adverse eventFAERS: 8US FAERS
4DizzinessFAERS: 5US FAERS
5Genital infection fungalFAERS: 5US FAERS
6VomitingFAERS: 5US FAERS
7Diabetic KetoacidosisFAERS: 4US FAERS
8Vulvovaginal mycotic infectionFAERS: 4US FAERS
9Acute kidney injuryFAERS: 3US FAERS
10Blood glucose increasedFAERS: 3US FAERS
11DehydrationFAERS: 3US FAERS
12Drug ineffectiveFAERS: 3US FAERS
13HeadacheFAERS: 3US FAERS
14Incorrect dose administeredFAERS: 3US FAERS
15PolyuriaFAERS: 3US FAERS
16Adverse eventFAERS: 2US FAERS
17Blood glucose abnormalFAERS: 2US FAERS
18Feeling abnormalFAERS: 2US FAERS
19IncontinenceFAERS: 2US FAERS
20MalaiseFAERS: 2US FAERS
21PalpitationsFAERS: 2US FAERS
22Product dose omissionFAERS: 2US FAERS
23PruritusFAERS: 2US FAERS
24PyelonephritisFAERS: 2US FAERS
25Abdominal discomfortFAERS: 1US FAERS
26AcneFAERS: 1US FAERS
27Alanine Aminotransferase IncreasedFAERS: 1US FAERS
28AlopeciaFAERS: 1US FAERS
29Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
30Back PainFAERS: 1US FAERS
31Benign Prostatic HyperplasiaFAERS: 1US FAERS
32Blood creatinine increasedFAERS: 1US FAERS
33Chest discomfortFAERS: 1US FAERS
34Circumstance or information capable of leading to medication errorFAERS: 1US FAERS
35Diabetes mellitus inadequate controlFAERS: 1US FAERS
36Drug dose omissionFAERS: 1US FAERS
37DyspepsiaFAERS: 1US FAERS
38DysuriaFAERS: 1US FAERS
39Genital discomfortFAERS: 1US FAERS
40Genital infectionFAERS: 1US FAERS
41HypotensionFAERS: 1US FAERS
42Low density lipoprotein increasedFAERS: 1US FAERS
43MyalgiaFAERS: 1US FAERS
44NocturiaFAERS: 1US FAERS
45Oral fungal infectionFAERS: 1US FAERS
46Oral painFAERS: 1US FAERS
47Oropharyngeal candidiasisFAERS: 1US FAERS
48PainFAERS: 1US FAERS
49Penile InfectionFAERS: 1US FAERS
50Penile erythemaFAERS: 1US FAERS
51Peripheral swellingFAERS: 1US FAERS
52Product availability issueFAERS: 1US FAERS
53Product communication issueFAERS: 1US FAERS
54Product dispensing issueFAERS: 1US FAERS
55Product use in unapproved indicationFAERS: 1US FAERS
56Product use issueFAERS: 1US FAERS
57Renal painFAERS: 1US FAERS
58Spinal StenosisFAERS: 1US FAERS
59TachycardiaFAERS: 1US FAERS
60UrticariaFAERS: 1US FAERS
61Vaginal DischargeFAERS: 1US FAERS
62Vulvovaginal erythemaFAERS: 1US FAERS
63Vulvovaginal painFAERS: 1US FAERS
64Vulvovaginal swellingFAERS: 1US FAERS
65Weight decreasedFAERS: 1US FAERS
66Wrong patient received productFAERS: 1US FAERS
67Wrong technique in product usage processFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.